alpha-l-Rhamnopyranose triacetate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: alpha-l-Rhamnopyranose triacetate
• 英文别名: (4,5-diacetyloxy-6-hydroxy-2-methyloxan-3-yl) acetate
• 化学式: C₁₂H₁₈O₈
• 分子量: 290.27
• InChiKey: QHOCNNVTMIFDFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy
  申请人：Aben Rene Wilhelmus Marie

  公开号：US20090227617A1

  公开（公告）日：2009-09-10

  The invention relates to novel esters and in particular to some novel esters of glucuronide prodrugs of anthracyclines having tunable water-solubility, their synthesis and use in tumor-selective chemotherapy. It appeared that in the final step in the synthesis of these prodrugs, i.e. the coupling of the glucuronide spacer moiety to the parent drug molecule, protection of the sugar hydroxyls is, surprisingly, no longer required. A process for the preparation of these unprotected sugar spacer moieties is also disclosed.

  该发明涉及新型酯类化合物，特别是一些新型葡萄糖醛酸盐前药的酯类化合物，其具有可调节的水溶性，以及它们在肿瘤选择性化疗中的合成和应用。在这些前药的合成的最后一步中，即将葡萄糖醛酸盐间隔基与母药分子偶联时，令人惊讶的是，不再需要保护糖羟基。还公开了一种制备这些未保护糖间隔基的过程。
• THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF
  申请人：SHANGHAI DONGXI ZHIHUI BIOLOGICAL MEDICINE CO., LTD.

  公开号：US20210087214A1

  公开（公告）日：2021-03-25

  The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.